Skip to main content
SANA
NASDAQ Life Sciences

Sana Biotechnology Details Q1 Results, Mayo Clinic Investment, and Clinical Progress Amidst Short Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.6
Mkt Cap
$950.046M
52W Low
$1.6
52W High
$6.55
52W Position info
125% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SANA has more than doubled off its 52-week low of $1.6.

Summary

Sana Biotechnology reported its first-quarter 2026 financial results, detailing a strategic $25 million equity investment from Mayo Clinic and positive clinical progress for its UP421 program, while also highlighting a cash runway into 2027.


Key Events · Financing and Capital Events · SANA

  • Q1 2026 Financials

    Reported a net loss of $47.2 million and a non-GAAP operating cash burn of $37.0 million for Q1 2026.

  • Strategic Equity Investment

    Secured an initial $25.0 million equity investment from Mayo Clinic as part of a collaboration to advance SC451, with an option for an additional $25.0 million.

  • Cash Position & Runway

    Ended Q1 with $101.1 million in cash, with a pro forma cash position of $128.9 million (including the Mayo investment and ATM activity), extending the expected cash runway into 2027.

  • Positive Clinical Data

    Announced positive 14-month follow-up results from a study of UP421 in type 1 diabetes, demonstrating survival and function of transplanted cells without immunosuppression.


Analysis · SANA · Life Sciences

This 8-K furnishes the company's Q1 2026 earnings press release, which provides crucial updates on its financial health and pipeline. While the concurrent 10-Q raised substantial doubt about the company's ability to continue as a going concern, this filing details a strategic $25 million equity investment from Mayo Clinic, which extends the cash runway into 2027. The press release also highlights positive 14-month clinical data for its UP421 program and significant progress towards Phase 1 trials for SC451 and SG293, which are vital for future financing and long-term viability.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SANA was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950M. The 52-week trading range was $1.60 to $6.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SANA - Latest Insights

SANA
Nov 05, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.44
Real-time Price: $2.30 info
Change: -$0.1394 (-6%) info
Market Cap: $686.164M info
SANA
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.30 info
Change: -$0.1094 (-5%) info
Market Cap: $686.164M info
SANA
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.85
Real-time Price: $2.30 info
Change: -$1.55 (-40%) info
Market Cap: $686.164M info
SANA
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.53
Real-time Price: $2.30 info
Change: -$1.23 (-35%) info
Market Cap: $686.164M info
SANA
Aug 10, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.53
Real-time Price: $2.30 info
Change: -$1.23 (-35%) info
Market Cap: $686.164M info